SGLT2 inhibitors: glucuretic treatment for type 2 diabetes

Clifford J. Bailey, Caroline Day

Research output: Contribution to journalArticlepeer-review


Sodium glucose co-transporter-2 (SGLT2) inhibitors offer a novel approach to treat diabetes by reducing hyperglycaemia via increased glucosuria. This approach reduces renal glucose reabsorption in the proximal renal tubules providing an insulin-independent mechanism to lower blood glucose. The glucuretics are advanced in clinical development and dapagliflozin has received most extensive study. Once daily dapaglifolozin as monotherapy or as add-on to metformin for 12-24 weeks in type 2 diabetic patients (baseline HbA 8-9%) reduced HbA by about 0.5-1%, accompanied by weight loss (2-3 kg) and without significant risk of hypoglycaemia. Dapagliflozin has reduced insulin requirement and improved glycaemic control without weight gain in insulin-treated patients. A mild osmotic diuresis associated with glucuretic therapy may account for a small increase in haematocrit (1-2%) and reduced blood pressure (2-5 mmHg). Dehydration and altered electrolyte balance have not been encountered. Urinary tract and genital infections increased in most studies with dapagliflozin, but were typically mild - resolving with selfmedication or standard intervention. Thus glucuretics provide a novel insulin-independent approach for control of hyperglycaemia which does not incur hypoglycaemia, promotes weight loss, may reduce blood pressure and offers compatibility with other glucose-lowering agents.
Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalBritish Journal of Diabetes and Vascular Disease
Issue number4
Publication statusPublished - Jul 2010


  • dapagliflozin diabetes
  • flozins
  • glucuretics
  • hypoglycaemic


Dive into the research topics of 'SGLT2 inhibitors: glucuretic treatment for type 2 diabetes'. Together they form a unique fingerprint.

Cite this